Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.

@article{Breccia2010SecondgenerationTK,
  title={Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.},
  author={Massimo Breccia and Francesca Palandri and Anna Paola Iori and Elisabetta Colaci and Roberto Latagliata and Fausto Castagnetti and Giovanni Fernando Torelli and Sara Usai and Veronica Valle and Giovanni Martinelli and Gianantonio Rosti and Robin Fo{\'a} and Michele Baccarani and Giuliana Alimena},
  journal={Leukemia research},
  year={2010},
  volume={34 2},
  pages={143-7}
}
Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs). Limited data exist on the possible effects of these drugs on subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outcome of 12 imatinib-resistant CML patients treated with dasatinib or nilotinib or both before allo-HSCT, was retrospectively analyzed. Patients were treated with second-generation… CONTINUE READING
15 Citations
18 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 18 references

Nilotinib. Clin Cancer Res 2008;14:4027–31

  • MW Deininger
  • 2008
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…